- Home
-
Press releases
-
Media academy
- Lung Cancer
- Breast Cancer
- Ovarian Cancer
- Head & Neck Cancer
- Targeted Therapy
Eric Pujade-Lauraine
Department of Hematology-Medical Oncology, Hôpital Hôtel-Dieu, Paris, France
LUME-OVAR is the first ovarian cancer trial where such an antiangiogenic compound is combined with chemo[therapy] and also delivered as an oral compound in the maintenance during two years.
BIBF 1120* will offer to patients, if it is approved, several advantages: First it’s oral in contrast to some other compounds, which must be delivered intravenously. While second, it has three different targets so it might be more effective than those compounds, which has only one target, such as VEGF. And third, and very importantly, particularly in patients who were treated during two years in maintenance for their cancer, it has a very favourable toxicity profile. And it is thus very important for patients to have a well tolerated compound when you take it during months and years.
Source for healthcare professionals: www.inoncology.com
* Nintedanib (BIBF 1120), afatinib (BIBW 2992) and volasertib (BI 6727) are investigational compounds. Their safety and efficacy have not yet been fully established.
